These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 39069431

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.
    Bhavnani SM, Hammel JP, Lakota EA, Liolios K, Trang M, Rubino CM, Steenbergen JN, Friedrich L, Tzanis E, Ambrose PG.
    Antimicrob Agents Chemother; 2024 Sep 04; 68(9):e0128123. PubMed ID: 39082883
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis.
    Wang K, Zhu Y, Xu F, Liu L, Liu L, Shi M, Nie J, Reinhart H, Liu J, Gao Y, Pu X.
    Eur J Pharm Sci; 2024 Apr 01; 195():106713. PubMed ID: 38295963
    [Abstract] [Full Text] [Related]

  • 5. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
    Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Hink R, Berry L, Schweizer F, Zhanel MA, Bay D, Lagacé-Wiens PRS, Walkty AJ, Lynch JP, Karlowsky JA.
    Drugs; 2020 Feb 01; 80(3):285-313. PubMed ID: 31970713
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluating omadacycline dosing regimens against drug-resistant pathogens including Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Wei XC, Zhao MF, Xiao X.
    J Chemother; 2024 Nov 01; 36(7):532-539. PubMed ID: 38591989
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects.
    Yang H, Huang Z, Chen Y, Zhu Y, Cao G, Wang J, Guo Y, Yu J, Wu J, Liu L, Deng J, Liu J, Reinhart H, Zhang J, Wu X.
    Front Pharmacol; 2022 Nov 01; 13():869237. PubMed ID: 35529438
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis.
    Xu G, Liu X, Wang J, Mei Y, Yang D, He C, Zhong L, Zhu J, Ding H, Fang L.
    J Chemother; 2024 Dec 01; 36(8):709-716. PubMed ID: 38650393
    [Abstract] [Full Text] [Related]

  • 10. Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics.
    Rodvold KA, Burgos RM, Tan X, Pai MP.
    Clin Pharmacokinet; 2020 Apr 01; 59(4):409-425. PubMed ID: 31773505
    [Abstract] [Full Text] [Related]

  • 11. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP).
    Cilloniz C, Torres A.
    Expert Opin Drug Metab Toxicol; 2023 Sep 01; 19(9):569-576. PubMed ID: 37728376
    [Abstract] [Full Text] [Related]

  • 12. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
    Huband MD, Pfaller MA, Shortridge D, Flamm RK.
    J Glob Antimicrob Resist; 2019 Dec 01; 19():56-63. PubMed ID: 30825698
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.
    Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB.
    Antimicrob Agents Chemother; 2014 Dec 01; 58(2):1127-35. PubMed ID: 24295985
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Rubio-Langre S, Aguilar-Sola S, Lorenzutti AM, San Andrés MI, De Lucas JJ, Litterio NJ.
    J Vet Pharmacol Ther; 2018 Dec 01; 41(6):861-870. PubMed ID: 30020535
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
    Yu W, Ji J, Xiao T, Ying C, Fang J, Shen P, Xiao Y.
    Drug Des Devel Ther; 2017 Dec 01; 11():1951-1956. PubMed ID: 28721014
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A, Isla A, Rodríguez-Gascón A.
    Int J Antimicrob Agents; 2015 Apr 01; 45(4):399-405. PubMed ID: 25700566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.